Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed
FcRn inhibitor IMVT-1402 drove high response rates in rheumatoid arthritis patients refractory to multiple RA drugs. Johnson & Johnson ended development of Imaavy in the indication after a Phase II failure.
Scrip - May 20, 2026

Optum Rx CEO Makes Case To Industry: Let’s Work Together
CEO Jon Mahrt said the pharmacy benefit manager has introduced new policies to increase pricing transparency and better align with partners and patients.
Scrip - May 20, 2026

Senate Democrats Say Medicare AI Pilot Program Is Not ‘WISeR’ For Seniors
A group of Democratic senators want to roll back a Medicare pilot program that uses AI to automate the approval process for several outpatient procedures. The Trump administration says the WISeR model targets fraud and waste, while opponents say it’s another tool for private companies to delay care.
Medtech Insight - May 20, 2026

‘Axe the Fax’: CMS Doubles Down On Efforts To Modernize Prior Authorization
The Centers for Medicare & Medicaid Services announced another push in the effort to reduce the time needed to obtain prior authorization (PA) from payers. The agency seems poised to apply significant pressure on payers across the board, and lab tests could be next.
Medtech Insight - May 20, 2026

Pfizer Moves Next-Gen Vaccine Into Phase III In Prevnar Lifecycle Strategy
The drugmaker is touting greater coverage with the 25-valent pneumococcal vaccine, PF-07872412, compared with the marketed 20-valent Prevnar 20 in a pediatric study.
Scrip - May 20, 2026

Mid-Market Healthcare Races Ahead On AI – But Cybersecurity Fears Are Holding Back Full Deployment
A new study finds mid-market healthcare companies are among the most aggressive AI adopters, yet security concerns are blocking 67% of firms from scaling further.
Medtech Insight - May 20, 2026

Medtronic To Buy SPR Therapeutics For $650M In Push To Expand Pain Portfolio
The deal adds a temporary peripheral nerve stimulation platform to Medtronic’s neuromodulation lineup, positioning the company to intervene earlier in patients’ chronic pain journeys.
Medtech Insight - May 20, 2026

Hantavirus Has Low Pandemic Risk But Moderna Stays Vigilant
Three deaths on board a cruise ship have caused concern, but the Andes hantavirus strain remains a low pandemic risk and vaccine firm Moderna will not accelerate development of its preclinical candidate.
Scrip - May 20, 2026

Samsung Bioepis Expands Into Japan With Ustekinumab Launch
Samsung Bioepis has taken a step into the Japanese biosimilars market with the launch of its SB17 ustekinumab rival to Stelara through local partner Nipro. However, it will face stiff competition from multiple other players.
Generics Bulletin - May 20, 2026

Shiseido Sees Green Shoots Of Recovery At US Business
Japanese cosmetics multinational Shiseido reports growing US sales in Q1 following a difficult 2025.
HBW Insight - May 20, 2026

Lupin Marks A Return To $1bn Annual US Sales
Lupin hit $1bn in US sales once before but then spent years clawing its way back. Now it's back, bigger, and betting biosimilars will keep the momentum going.
Generics Bulletin - May 20, 2026

GHO And CBC Merger Creates World’s Largest Healthcare Investor
The pact will combine the financial firms’ complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
Scrip - May 20, 2026

For European Biosimilars, ‘Science Prevails Here’
Closing Medicines for Europe’s biosimilars conference, EMA chief medical officer Steffen Thirstrup said biosimilar regulation must continue evolving with science, as Europe enters a “Biosimilars 2.0” era shaped by comparability, convergence and uneven access challenges.
Generics Bulletin - May 20, 2026

Krka: Generics Winners Must Guarantee Uninterrupted Supply
Krka CEO Jože Colari? tells Generics Bulletin why vertical integration, manufacturing continuity and portfolio breadth are becoming decisive advantages in generics, as the Slovenian firm scales investment across Europe, India and China.
Generics Bulletin - May 20, 2026

Labio 4.0: Integration From The Outset
How Morpho, Alfasigma’s CDMO business unit, is rethinking pharmaceutical development through integrated analytics, formulation, and GMP manufacturing.
Scrip - May 20, 2026

The Biopharma A List: Taking The Pulse of Newco Creation In 2025
Biopharma Series A financing remained steady in 2025, reflecting stable new company creation year over year.
In Vivo - May 20, 2026

Ibuprofen And Diclofenac Added To EU Priority Water Pollutants List
The EU has added ibuprofen and diclofenac to its list of priority water pollutants under revised water legislation, while leaving widely used OTC ingredients such as paracetamol, aspirin and naproxen off the list.
HBW Insight - May 20, 2026

What’s Next For US FDA: Can Acting FDA Chief Diamantas Repair Makary’s Damage Before Drift Sets In?
With the former commissioner’s top lieutenants being replaced, Acting Commissioner Kyle Diamantas has moved fast to clean house and pacify career staff. But reversing 14 months of norm erosion is harder than changing the nameplate, if it’s even possible at all.
In Vivo - May 20, 2026

Takeda Reels From $885m Amitiza Reverse-Payment Verdict
Takeda faces more than $2.5bn in potential exposure after a landmark Amitiza pay-for-delay verdict that found its Par settlement delayed generic competition through a non-cash reverse payment and implicit no-AG pact.
Scrip - May 20, 2026

Eisai Expects Leqembi Expansion Through Iqlik And BBM Diagnosis
Growth for mainstays and Alzheimer's drug Leqembi helped Eisai's revenue double, with new formulations, indications and diagnostic tools seen boosting the amyloid-targeting antibody this fiscal year.
Scrip - May 20, 2026

Diamantas Extends Olive Branch To US FDA Staff Amid Senior Leader Shake-Up
Acting CDER Director Tracy Beth Høeg, who had been in the position about six months, was one of several senior leaders appointed by former commissioner Martin Makary to depart.
HBW Insight - May 20, 2026